Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Fifteen new option listings on December 21st » 08:30
12/21/22
12/21
08:30
12/21/22
08:30
CLSC

Cobalis Corp

$20.70 /

+0.02 (+0.10%)

, MCBS

MetroCity Bankshares

$21.09 /

-0.035 (-0.17%)

, OABI

OmniAb

$3.31 /

+0.05 (+1.53%)

, ORRF

Orrstown Financial

$25.47 /

+0.42 (+1.68%)

, PKBK

Parke Bancorp

$20.20 /

-0.295 (-1.44%)

, PNT

Point Biopharma

$6.81 /

+0.315 (+4.85%)

, RBB

RBB Bancorp

$20.80 /

-0.37 (-1.75%)

, RMR

RMR Group

$28.34 /

+0.09 (+0.32%)

New option listings for…

New option listings for December 21st include CLSA ETF (CLSA), Cobalis Corporation (CLSC), CLVSQ Stock (CLVSQ), DFIC ETF (DFIC), GSUS ETF (GSUS), JIRE ETF (JIRE), Metrocity Bankshares Inc (MCBS), OmniAb (OABI), Orrstown Financial (ORRF), PFIX ETF (PFIX), Parke Bancorp (PKBK), POINT Biopharma Global Inc (PNT), RBB Bancorp (RBB), RMR Group (RMR), and UHALB Stock (UHALB).

ShowHide Related Items >><<
RMR RMR Group
$28.34 /

+0.09 (+0.32%)

RBB RBB Bancorp
$20.80 /

-0.37 (-1.75%)

PNT Point Biopharma
$6.81 /

+0.315 (+4.85%)

PKBK Parke Bancorp
$20.20 /

-0.295 (-1.44%)

ORRF Orrstown Financial
$25.47 /

+0.42 (+1.68%)

OABI OmniAb
$3.31 /

+0.05 (+1.53%)

CLSC Cobalis Corp
$20.70 /

+0.02 (+0.10%)

MCBS MetroCity Bankshares
$21.09 /

-0.035 (-0.17%)

OABI OmniAb
$3.31 /

+0.05 (+1.53%)

12/20/22 Truist
OmniAb initiated with a Buy at Truist
12/16/22 Credit Suisse
OmniAb initiated with an Outperform at Credit Suisse
11/29/22 SVB Securities
OmniAb initiated with an Outperform at SVB Securities
11/28/22 Stifel
OmniAb initiated with a Buy at Stifel
ORRF Orrstown Financial
$25.47 /

+0.42 (+1.68%)

11/17/22 Piper Sandler
Orrstown Financial resumed with a Neutral at Piper Sandler
PKBK Parke Bancorp
$20.20 /

-0.295 (-1.44%)

PNT Point Biopharma
$6.81 /

+0.315 (+4.85%)

12/14/22 Raymond James
Point Biopharma initiated with an Outperform at Raymond James
11/30/22 SVB Securities
Point Biopharma initiated with an Outperform at SVB Securities
11/15/22 Truist
Point Biopharma price target lowered to $14 from $22 at Truist
11/14/22 Piper Sandler
Point Biopharma price target lowered to $14 from $17 at Piper Sandler
RBB RBB Bancorp
$20.80 /

-0.37 (-1.75%)

03/29/22 Piper Sandler
RBB Bancorp downgraded to Underweight from Neutral at Piper Sandler
02/23/22 Janney Montgomery Scott
RBB Bancorp downgraded to Neutral from Buy at Janney Montgomery Scott
12/30/21 Piper Sandler
RBB Bancorp price target raised to $27.50 from $26 at Piper Sandler
RMR RMR Group
$28.34 /

+0.09 (+0.32%)

11/21/22 B. Riley
RMR Group price target lowered to $42 from $44 at B. Riley
08/09/22 Oppenheimer
RMR Group assumed with a Perform at Oppenheimer
05/20/22 RBC Capital
RMR Group price target lowered to $32 from $36 at RBC Capital
05/13/22 B. Riley
RMR Group price target raised to $44 from $42 at B. Riley
RMR RMR Group
$28.34 /

+0.09 (+0.32%)

RBB RBB Bancorp
$20.80 /

-0.37 (-1.75%)

PNT Point Biopharma
$6.81 /

+0.315 (+4.85%)

ORRF Orrstown Financial
$25.47 /

+0.42 (+1.68%)

MCBS MetroCity Bankshares
$21.09 /

-0.035 (-0.17%)

  • 14
    Sep
RMR RMR Group
$28.34 /

+0.09 (+0.32%)

PNT Point Biopharma
$6.81 /

+0.315 (+4.85%)

OABI OmniAb
$3.31 /

+0.05 (+1.53%)

Initiation
OmniAb initiated with a Buy at Truist » 07:32
12/20/22
12/20
07:32
12/20/22
07:32
OABI

OmniAb

$3.24 /

-0.255 (-7.30%)

Truist analyst Robyn…

Truist analyst Robyn Karnauskas initiated coverage of OmniAb with a Buy rating and $10 price target. Unlike many SMID names, Karnauskas sees less binary risk and instead see steady progression to the firm's price target as OmniAb secures additional partners with improving economics as well as increased clarity on revenue streams from royalties and development milestones, the analyst tells investors in a research note.

ShowHide Related Items >><<
OABI OmniAb
$3.24 /

-0.255 (-7.30%)

OABI OmniAb
$3.24 /

-0.255 (-7.30%)

12/16/22 Credit Suisse
OmniAb initiated with an Outperform at Credit Suisse
11/29/22 SVB Securities
OmniAb initiated with an Outperform at SVB Securities
11/28/22 Stifel
OmniAb initiated with a Buy at Stifel
10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
OABI OmniAb
$3.24 /

-0.255 (-7.30%)

Initiation
OmniAb initiated with an Outperform at Credit Suisse » 06:56
12/16/22
12/16
06:56
12/16/22
06:56
OABI

OmniAb

$3.48 /

-0.03 (-0.85%)

Credit Suisse analyst…

Credit Suisse analyst Tiago Fauth initiated coverage of OmniAb with an Outperform rating and $13 price target. The analyst expects the company's "flexibility and diversity of the multispecies platform" to drive growth. At the current valuation, the market is assigning value to some of the 25 clinical/approved programs but not to the company's remaining 257 preclinical programs, as there is no information on any of these programs, Fauth tells investors in a research note.

ShowHide Related Items >><<
OABI OmniAb
$3.48 /

-0.03 (-0.85%)

OABI OmniAb
$3.48 /

-0.03 (-0.85%)

11/29/22 SVB Securities
OmniAb initiated with an Outperform at SVB Securities
11/28/22 Stifel
OmniAb initiated with a Buy at Stifel
10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
OABI OmniAb
$3.48 /

-0.03 (-0.85%)

Conference/Events
OmniAb to participate in a conference call with Benchmark » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
OABI

OmniAb

$3.91 /

-0.06 (-1.51%)

Healthcare Analyst…

Healthcare Analyst Wasserman holds a conference call with CEO Foehr and CFO Gustafson on December 6 hosted by Benchmark.

ShowHide Related Items >><<
OABI OmniAb
$3.91 /

-0.06 (-1.51%)

OABI OmniAb
$3.91 /

-0.06 (-1.51%)

11/29/22 SVB Securities
OmniAb initiated with an Outperform at SVB Securities
11/28/22 Stifel
OmniAb initiated with a Buy at Stifel
10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
OABI OmniAb
$3.91 /

-0.06 (-1.51%)

Conference/Events
OmniAb to participate in a conference call with Benchmark » 16:39
12/05/22
12/05
16:39
12/05/22
16:39
OABI

OmniAb

$3.91 /

-0.06 (-1.51%)

Healthcare Analyst…

Healthcare Analyst Wasserman holds a conference call with CEO Foehr and CFO Gustafson on December 6 hosted by Benchmark.

ShowHide Related Items >><<
OABI OmniAb
$3.91 /

-0.06 (-1.51%)

OABI OmniAb
$3.91 /

-0.06 (-1.51%)

11/29/22 SVB Securities
OmniAb initiated with an Outperform at SVB Securities
11/28/22 Stifel
OmniAb initiated with a Buy at Stifel
10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
OABI OmniAb
$3.91 /

-0.06 (-1.51%)

Hot Stocks
Hillstream BioPharma announces development of Knob Quatrabodies » 08:48
12/01/22
12/01
08:48
12/01/22
08:48
HILS

Hillstream BioPharma

/

+

, OABI

OmniAb

$3.53 /

+0.72 (+25.62%)

Hillstream BioPharma…

Hillstream BioPharma (HILS) announced the development of proprietary targeted biologics, Knob Quatrabodies against PD-1. Hillstream signed separate collaboration agreements with a subsidiary of OmniAb, Inc. (OABI) and with Minotaur Therapeutics to advance Picobodies against novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1. The technologies of Hillstream and Minotaur will be combined under a previously disclosed license from OmniAb to discover, develop and advance biotherapeutics against high-value validated targets. Picobodies are antibody "knob" domains comprised of cysteine-rich ultralong complementary determining region H3 sequences of 30-40 amino acids, which have the potential to access challenging epitopes better than full size antibodies can. By combining Quatramers with their long half-life coated with a PD-1 Picobody to create HSB-1940, Hillstream believes it could more efficiently target novel epitopes with greater binding affinity than approved biologics. Targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology therapeutics market with additional IO targets after PD-L1.

ShowHide Related Items >><<
HILS Hillstream BioPharma
/

+

HILS Hillstream BioPharma
/

+

OABI OmniAb
$3.53 /

+0.72 (+25.62%)

11/29/22 SVB Securities
OmniAb initiated with an Outperform at SVB Securities
11/28/22 Stifel
OmniAb initiated with a Buy at Stifel
10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
  • 12
    Jan
OABI OmniAb
$3.53 /

+0.72 (+25.62%)

HILS Hillstream BioPharma
/

+

Syndicate
OmniAb files to sell 36.35M shares of common stock for holders  16:56
11/30/22
11/30
16:56
11/30/22
16:56
OABI

OmniAb

$3.53 /

+0.72 (+25.62%)

 
ShowHide Related Items >><<
OABI OmniAb
$3.53 /

+0.72 (+25.62%)

11/29/22 SVB Securities
OmniAb initiated with an Outperform at SVB Securities
11/28/22 Stifel
OmniAb initiated with a Buy at Stifel
10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
OABI OmniAb
$3.53 /

+0.72 (+25.62%)

Initiation
OmniAb initiated with an Outperform at SVB Securities » 06:08
11/29/22
11/29
06:08
11/29/22
06:08
OABI

OmniAb

$2.88 /

+0.29 (+11.20%)

SVB Securities analyst…

SVB Securities analyst Puneet Souda initiated coverage of OmniAb with an Outperform rating and $6 price target.

ShowHide Related Items >><<
OABI OmniAb
$2.88 /

+0.29 (+11.20%)

11/28/22 Stifel
OmniAb initiated with a Buy at Stifel
10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
OABI OmniAb
$2.88 /

+0.29 (+11.20%)

Initiation
OmniAb initiated with a Buy at Stifel » 05:57
11/28/22
11/28
05:57
11/28/22
05:57
OABI

OmniAb

$2.59 /

-0.2 (-7.17%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey initiated coverage of OmniAb with a Buy rating and $12 price target. OmniAb "represents the construction of a high-throughput antibody discovery platform" via over 10 years of focused investment and strategic acquisitions, Willey tells investors in a research note. The analyst believes the spin-off of OmniAb from Ligand "creates an opportunity to unlock additional value and better-position the company for future growth."

ShowHide Related Items >><<
OABI OmniAb
$2.59 /

-0.2 (-7.17%)

10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
OABI OmniAb
$2.59 /

-0.2 (-7.17%)

Over a quarter ago
On The Fly
Biotech Alert: Searches spiking for these stocks today » 11:01
11/04/22
11/04
11:01
11/04/22
11:01
ARCT

Arcturus Therapeutics

$23.62 /

+1.57 (+7.12%)

, UTHR

United Therapeutics

$267.10 /

+1.64 (+0.62%)

, LGND

Ligand

$62.58 /

-0.215 (-0.34%)

, NVO

Novo Nordisk

$113.39 /

-0.67 (-0.59%)

, GTHX

G1 Therapeutics

$8.18 /

+0.26 (+3.28%)

, CSLLY

CSL

$87.61 /

-1.12 (-1.26%)

, OABI

OmniAb

$2.50 /

-0.095 (-3.66%)

These names in the…

ShowHide Related Items >><<
UTHR United Therapeutics
$267.10 /

+1.64 (+0.62%)

NVO Novo Nordisk
$113.39 /

-0.67 (-0.59%)

LGND Ligand
$62.58 /

-0.215 (-0.34%)

GTHX G1 Therapeutics
$8.18 /

+0.26 (+3.28%)

CSLLY CSL
$87.61 /

-1.12 (-1.26%)

ARCT Arcturus Therapeutics
$23.62 /

+1.57 (+7.12%)

ARCT Arcturus Therapeutics
$23.62 /

+1.57 (+7.12%)

11/03/22 Citi
Arcturus Therapeutics upgraded to Buy at Citi after CSL deal
11/03/22 Citi
Arcturus Therapeutics upgraded to Buy from Neutral at Citi
11/02/22 Barclays
Arcturus Therapeutics upgraded to Equal Weight from Underweight at Barclays
11/02/22 Cantor Fitzgerald
Arcturus Therapeutics price target raised to $44 from $39 at Cantor Fitzgerald
UTHR United Therapeutics
$267.10 /

+1.64 (+0.62%)

11/03/22 Wedbush
United Therapeutics price target raised to $305 from $250 at Wedbush
11/03/22 Oppenheimer
United Therapeutics price target raised to $375 from $325 at Oppenheimer
11/03/22 H.C. Wainwright
United Therapeutics price target raised to $300 from $255 at H.C. Wainwright
10/11/22 Morgan Stanley
United Therapeutics initiated with an Overweight at Morgan Stanley
LGND Ligand
$62.58 /

-0.215 (-0.34%)

10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
10/25/22 Barclays
Ligand price target lowered to $150 from $157 at Barclays
09/02/22 Roth MKM
Ligand price target lowered to $175 from $185 at Roth Capital
07/05/22 Barclays
Ligand price target lowered to $157 from $165 at Barclays
NVO Novo Nordisk
$113.39 /

-0.67 (-0.59%)

11/03/22 Credit Suisse
Novo Nordisk price target raised to DKK 860 from DKK 820 at Credit Suisse
10/14/22 Barclays
Novo Nordisk price target raised to DKK 850 from DKK 825 at Barclays
09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
GTHX G1 Therapeutics
$8.18 /

+0.26 (+3.28%)

11/02/22 H.C. Wainwright
G1 Therapeutics price target lowered to $57 from $67 at H.C. Wainwright
09/16/22 Wedbush
G1 Therapeutics price target raised to $25 from $20 at Wedbush
CSLLY CSL
$87.61 /

-1.12 (-1.26%)

09/23/22 Jefferies
CSL upgraded to Buy from Hold at Jefferies
08/09/22 Goldman Sachs
CSL reinstated with a Neutral at Goldman Sachs
OABI OmniAb
$2.50 /

-0.095 (-3.66%)

UTHR United Therapeutics
$267.10 /

+1.64 (+0.62%)

NVO Novo Nordisk
$113.39 /

-0.67 (-0.59%)

LGND Ligand
$62.58 /

-0.215 (-0.34%)

GTHX G1 Therapeutics
$8.18 /

+0.26 (+3.28%)

ARCT Arcturus Therapeutics
$23.62 /

+1.57 (+7.12%)

NVO Novo Nordisk
$113.39 /

-0.67 (-0.59%)

ARCT Arcturus Therapeutics
$23.62 /

+1.57 (+7.12%)

UTHR United Therapeutics
$267.10 /

+1.64 (+0.62%)

NVO Novo Nordisk
$113.39 /

-0.67 (-0.59%)

ARCT Arcturus Therapeutics
$23.62 /

+1.57 (+7.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.